낭포성섬유증 시장 예측(-2030년) : 약물 종류별, 치료법별, 투여 경로별, 유통 채널별, 지역별 세계 분석

According to Stratistics MRC, the Global Cystic Fibrosis Market is accounted for $11.49 billion in 2023 and is expected to reach $47.30 billion by 2030 growing at a CAGR of 22.4% during the forecast period. A genetic mutation is the cause of the inherited disease known as cystic fibrosis (CF). Certain bodily liquids' protein secretion is regulated by genes. This affects different organs in the body, which tends to thicken mucus and sweat. Moreover, this illness modifies the electrolyte transport system, which results in the absorption of sodium and water by cells and causes issues with the glands responsible for producing sweat and mucus.

According to the Cystic Fibrosis Patient Registry, it is estimated that more than 30,000 people are currently suffering from this condition in the U.S. and it is estimated that about 70,000 people are suffering from it across the globe.

Market Dynamics:

Driver:

Personalized medicine and genetic testing

The ability to precisely identify CFTR gene mutations in individual patients has been made possible by advances in genetic sequencing technologies and genetic testing. With the help of this individualized approach, medical professionals can customize treatment plans and offer the best medications depending on each patient's particular genetic profile. Additionally, the market is further propelled by the emphasis on personalized medicine, which raises patient satisfaction and treatment effectiveness.

Restraint:

Expensive medical care

The cost of treating cystic fibrosis can be extremely high, sometimes amounting to hundreds of thousands of dollars per year, particularly for CFTR modulators. These excessive expenses may put pressure on insurers and healthcare systems, making it more difficult to provide access to all patients. Furthermore, concerns about these treatments' long-term affordability are also brought up by cost, which could have an impact on market expansion.

Opportunity:

Improvements in medication delivery systems

Treatment administration has been enhanced by advances in drug delivery, such as intelligent inhalers and effective nebulizers. However, since they guarantee that patients get the full benefit of their treatments, these practical and efficient drug delivery strategies improve patient experience, promote adherence, and subsequently aid in market expansion.

Threat:

Complex therapy plans

Treatment plans for cystic fibrosis frequently entail a complicated mix of drugs, therapies, and lifestyle modifications. This complexity has the potential to overwhelm patients and result in poor adherence to treatment, which will ultimately compromise the efficacy of therapies and patient outcomes. Moreover, healthcare expenses may rise, and exacerbations may occur more frequently as a result of noncompliance.

COVID-19 Impact:

The COVID-19 pandemic caused major disruptions in patient care, clinical trials, and healthcare systems, which in turn affected the cystic fibrosis market. The pandemic put a strain on healthcare resources, delayed the introduction of new treatments, and postponed research and development. Individuals diagnosed with cystic fibrosis, who were regarded as a high-risk population, experienced increased health risks and frequently had limited access to necessary medical care. Furthermore, the pandemic's economic effects put more strain on healthcare systems and patients' finances, which might have an impact on the cost and accessibility of cystic fibrosis treatments.

The Cystic Fibrosis Transmembrane Conductance Regulator Modulators segment is expected to be the largest during the forecast period

CFTR modulators are expected to hold the largest share in the cystic fibrosis market due to their transformative impact, which is expected to represent a paradigm shift in the treatment of this complex and challenging genetic disease. Moreover, treatment for cystic fibrosis has been transformed by CFTR modulators such as Trikafta. These medications improve mucus clearance and chloride transport by addressing the underlying genetic defect that causes cystic fibrosis. For many patients with particular genetic mutations, CFTR modulators greatly improve lung function, lower exacerbations, and improve quality of life.

The Inhaled segment is expected to have the highest CAGR during the forecast period

The inhaled segment of the cystic fibrosis market has the highest CAGR. Because inhaled therapies deliver medication directly to the lungs in a targeted and effective manner, they have become increasingly popular in recent years. Inhalers are commonly used in these therapies to deliver medications that assist in controlling the symptoms of cystic fibrosis. Additionally, the significant growth of the inhaled segment can be attributed to various factors, such as the progression of inhalation technology, heightened consciousness regarding the advantages of inhalation treatments, and the creation of novel medications especially intended for inhalation administration.

Region with largest share:

North America holds the largest market share for cystic fibrosis. This is explained by a number of factors that support the region's market dominance. First off, both the general public and medical professionals in North America are highly aware of cystic fibrosis, and the continent has a well-established healthcare infrastructure. This makes it easier to diagnose and treat patients early, which expands the patient pool and raises the market for cystic fibrosis treatments. Furthermore, there are many pharmaceutical companies and research facilities in the area that are actively working to develop cutting-edge cystic fibrosis treatments. The availability of cutting-edge medical equipment and advantageous reimbursement practices also boost the market share of the area.

Region with highest CAGR:

The Asia-Pacific region is anticipated to have the highest CAGR in the cystic fibrosis market. This region is seeing a rise in the number of cases of cystic fibrosis and is seeing rapid growth in a number of industries, including healthcare. The region's rapid growth is attributed to a number of factors, including expanding public awareness of cystic fibrosis, enhancing healthcare infrastructure, and rising healthcare costs. Moreover, governments in nations such as China and India are implementing programs aimed at improving healthcare affordability and accessibility, which will benefit patients with cystic fibrosis by providing better options for diagnosis and treatment.

Key players in the market

Some of the key players in Cystic Fibrosis market include: Pharmaxis Ltd , Gilead Sciences, Inc., Teva Pharmaceuticals, Genentech Inc , AbbVie Inc., Mylan N.V, Viatris Inc., Novartis AG, Allergan PLC, Pfizer Inc, Nestle Health Science, Hoffmann-La Roche AG , BayerAG, Vertex Pharmaceuticals Incorporated, AstraZeneca , Chiesi Farmaceutici SpA and Horizon Therapeutic Plc.

Key Developments:

In October 2023, Teva Pharmaceuticals and Sanofi have announced an agreement to jointly develop and commercialise a treatment for inflammatory bowel disease, with the deal potentially worth up to $1.5bn.The candidate, Teva's TEV'574, is an anti-TL1A therapy currently being evaluated in phase 2b clinical trials as a treatment for ulcerative colitis and Crohn's disease, the two main types of inflammatory bowel disease.

In October 2023, Viatris Inc., a global healthcare company, today announced it has received an offer for the divestiture of substantially all of its Over-the-Counter (OTC) business, and has entered into definitive agreements to divest its Women's Healthcare business, its Active Pharmaceutical Ingredients (API) business in India and commercialization rights in certain non-core markets that were acquired as part of the Upjohn Transaction.

In September 2023, PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical today announced a new multi-target collaboration and license agreement with U.S.-based Genentech, a member of the Roche Group, focused on the discovery and development of novel macrocyclic peptide-radioisotope ("peptide-RI") drug conjugates.

Drug Classes Covered:

• Pancreatic Enzyme Supplements
• Mucolytic
• Bronchodilators
• Antibiotics
• Cystic Fibrosis Transmembrane Conductance Regulator Modulators
• Other Drug Classes

Treatment Methods Covered:

• Medication
• Devices

Route of Administrations Covered:

• Oral
• Inhaled

Distribution Channels Covered:

• Hospital
• Drug Stores
• Retail Pharmacies
• Other Distribution Channels

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Cystic Fibrosis Market, By Drug Class

• 5.1 Introduction
• 5.2 Pancreatic Enzyme Supplements
• 5.3 Mucolytic
• 5.4 Bronchodilators
• 5.5 Antibiotics
• 5.6 Cystic Fibrosis Transmembrane Conductance Regulator Modulators
• 5.7 Other Drug Classes

6 Global Cystic Fibrosis Market, By Treatment Method

• 6.1 Introduction
• 6.2 Medication
• 6.3 Devices

7 Global Cystic Fibrosis Market, By Route of Administration

• 7.1 Introduction
• 7.2 Oral
• 7.3 Inhaled

8 Global Cystic Fibrosis Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Hospital
• 8.3 Drug Stores
• 8.4 Retail Pharmacies
• 8.5 Other Distribution Channels

9 Global Cystic Fibrosis Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Pharmaxis Ltd
• 11.2 Gilead Sciences, Inc.
• 11.3 Teva Pharmaceuticals
• 11.4 Genentech Inc
• 11.5 AbbVie Inc.
• 11.6 Mylan N.V
• 11.7 Viatris Inc.
• 11.8 Novartis AG
• 11.9 Allergan PLC
• 11.10 Pfizer Inc
• 11.11 Nestle Health Science
• 11.12 Hoffmann-La Roche AG
• 11.13 BayerAG
• 11.14 Vertex Pharmaceuticals Incorporated
• 11.15 AstraZeneca
• 11.16 Chiesi Farmaceutici SpA
• 11.17 Horizon Therapeutic Plc.